Period Pills for menstrual regulation using a two-drug approach
Official title: Period Pills for Menstrual Regulation: A New Reproductive Health Option
Run by University of California, San Francisco · NCT07671989 · Data updated 2026-11-12
This study tests whether taking a combination of mifepristone and misoprostol can help people with a late or missed period, who do not want to confirm pregnancy.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 2 sites (Oakland, California and 1 other locations) |
| Status | Recruiting |
| Started | June 22, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | May 31, 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07671989 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18 or older who have had regular periods recently, have a late period by up to 21 days, and do not want to be pregnant or verify pregnancy status.
✕Probably not a fit
People who are actively trying to become pregnant or those who prefer not to use hormonal or pill-based menstrual regulation may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective study will recruit up to 100 participants who have a late period and do not wish to verify pregnancy. Participants will take mifepristone followed by misoprostol as a means of menstrual regulation and potential pregnancy loss if pregnant. The study focuses on feasibility and acceptability of this approach as a fertility-regulation option prior to pregnancy verification, conducted at UCSF ANSIRH in Oakland and at Roanoke Health Center in Roanoke. Outcomes will include participant-reported acceptability, ease of use, and any safety considerations relevant to outpatient use. The research is led by UCSF investigators with collaborators at the listed sites to understand real-world use of period pills in this context.
Why it matters
Potential benefit: If successful, the approach could offer a acceptable option for menstrual regulation and may increase access to timely period restoration for people with late or missed periods.
How similar studies have gone: Prior clinical practice has used period pills in some settings, but this specific acceptability-focused, observational approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be 18 years old or older * Read and speak English * Know the date of their last menstrual period within 2 days * Have a period that is late by up to 21 days * Must have had regular periods in the last 4 months * Does not want to be pregnant * Does not want to verify pregnancy status * Understand that if they are pregnant, the pills will end their pregnancy * Does not have contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable) Exclusion Criteria: * Under 18 years old * Does not read and speak English * Does not know the date of their last menstrual period within 2 days * Has not had regular periods in the last 4 months * Wants to be pregnant * Wants to verify pregnancy status * Does not display understanding that if they are pregnant, the pills will end their pregnancy * Has any contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable)
Where it's running
-
Roanoke Health Center
Roanoke, Virginia, United States Recruiting -
UCSF Advancing New Standards in Reproductive Health (ANSIRH)
Oakland, California, United States Active not recruiting
Study contacts
- Principal investigator: Ushma D Upadhyay, PhD, MPH — University of California, San Francisco
- Study coordinator: Ushma D Upadhyay, PhD, MPH
- Email: ushma.upadhyay@ucsf.edu
- Phone: 415-353-4626
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.